Clinical Trials on C. Diff. Infections

Total 56671 results

AbbVie

Completed

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis (EXPEDITION-8)

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, Czechia, France, Greece, Hungary, Ireland, Israel, Italy, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Spain, Taiwan, United Kingdom, Vietnam
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment (EXPEDITION-5)

Hepatitis C Virus (HCV)

United States, Canada, Germany, Greece, Italy, Korea, Republic of, Poland, Puerto Rico, Spain, Sweden
Novartis Pharmaceuticals

Completed

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

Chronic Hepatitis C Genotype-1 Relapse

Belgium, United States, Germany, Spain, Puerto Rico, Taiwan, Australia
Johns Hopkins University
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Completed

CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS (CHAMPS)

Human Immunodeficiency Virus | Hepatitis C Virus Infection, Response to Therapy of

United States
Hannover Medical School
AbbVie

Terminated

MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV

Hepatitis C, Chronic

Germany
Catherine Anne Chappell
Gilead Sciences

Recruiting

Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (STORC)

Hepatitis C, Chronic | Pregnancy; Infection

United States, Canada
AbbVie

Completed

Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis (EASY)

Hepatitis C Virus (HCV)

Russian Federation
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Chronic Hepatitis C | Hepatitis C Virus | Compensated Cirrhosis
Kirby Institute

Completed

Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting (SHARP-P)

Hepatitis C, Chronic

Australia
Mohamed Saad

Unknown

Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C

HCV Infection

Egypt
Phillip Coffin, MD, MIA
National Institute on Drug Abuse (NIDA)

Completed

Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs (BYE-C)

Chronic Hepatitis C

United States
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects (HEC110114)

Chronic Hepatitis C

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

HCV

China
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects (HEC110114)

Chronic Hepatitis C

China
American Research Corporation
AbbVie

Completed

A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study (HEARTLAND)

Chronic Hepatitis C
Fundacion SEIMC-GESIDA

Withdrawn

A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A (C-RESCUE)

HCV

Spain
Merck Sharp & Dohme LLC

Terminated

Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)

Chronic Hepatitis C
Bristol-Myers Squibb

Completed

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Chronic Hepatitis C

United States, Argentina
Gilead Sciences

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Chronic Hepatitis C

United States, Puerto Rico
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Chronic Hepatitis C

United States
Bristol-Myers Squibb

Completed

A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Chronic Hepatitis C

United States
Arrow Therapeutics
DDS, Dundee; David Mutimer, Birmingham; Ed Gane, ACS New Zealand

Terminated

A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers (CP104)

Chronic Hepatitis C

New Zealand, United Kingdom
Hasselt University
Jessa Hospital; Ziekenhuis Netwerk Antwerpen (ZNA); Ziekenhuis Oost-Limburg; Algemeen... and other collaborators

Recruiting

HCV Reinfection After DAA Therapy in PWID in Belgium (REINF_HCV)

Drug Use | Hepatitis C Virus Infection, Response to Therapy of

Belgium
Assiut University

Completed

Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin

Liver Cirrhoses | Chronic Hepatitis c | Directly Acting Antivirals

Egypt
University of Maryland, Baltimore
Gilead Sciences; Unity Health Care, Inc.

Completed

Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience (RESOLVE)

Chronic Hepatitis C

United States
Azienda Ospedaliero-Universitaria di Parma
AbbVie

Completed

Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) Therapy

Chronic Hepatitis C

Italy
Alios Biopharma Inc.
Alexion

Completed

A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers

Chronic Hepatitis C

France
Gilead Sciences

Completed

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (LEPTON)

Chronic Hepatitis C

New Zealand
Medical University of Vienna

Completed

Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC) (AURIC)

Cirrhosis | Chronic Hepatitis C

Austria
TCM Biotech International Corp.

Withdrawn

The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)

Chronic Hepatitis C

Taiwan, China
ANRS, Emerging Infectious Diseases

Completed

French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin (CUPIC)

Chronic Hepatitis C

France
Foundation for Liver Research
Janssen-Cilag B.V.

Completed

Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms (ETIM)

Chronic Hepatitis C

Netherlands
Third Affiliated Hospital, Sun Yat-Sen University

Completed

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients

Chronic Hepatitis C

China
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) (FUSION)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico
Valneva Austria GmbH

Completed

Virological Response Study of the HCV Vaccine IC41

Chronic Hepatitis C

Germany, Poland, Romania
Azienda Ospedaliero-Universitaria di Parma

Completed

Effect of Boceprevir on HCV-specific T Cell Responses (Boce-Par)

Chronic Hepatitis C

Italy
Bristol-Myers Squibb

Completed

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Chronic Hepatitis C

United States, Puerto Rico
Azienda Ospedaliera San Camillo Forlanini

Completed

HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b (genotype)

Chronic Hepatitis C

Italy
Májbetegekért Alapítvány
Hoffmann-La Roche

Unknown

Continuing Treatment With Pegasys and Copegus

Chronic Hepatitis C

Hungary
Macfarlane Burnet Institute for Medical Research...
National Health and Medical Research Council, Australia; Gilead Sciences; The... and other collaborators

Recruiting

Eliminate Hepatitis C/EC Partnership Evaluation Protocol

Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis c

Australia
Merck Sharp & Dohme LLC

Completed

Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)

Hepatitis C
Hospital St. Joseph, Marseille, France

Completed

Screening for Chronic Hepatitis C Virus in Hospitalized Patients (DeViCHO)

Hepatitis C

France
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Atea Pharmaceuticals, Inc.

Completed

Study of AT-527 in Healthy and HCV-Infected Subjects

Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C

Belgium, Moldova, Republic of
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
Universidad de Antioquia

Unknown

Effect of Strategies for the Treatment of Chronic Hepatitis C in Colombia (HEPCSTRATEGY)

Hepatitis C

Colombia
R-Pharm

Completed

Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study) (PIONEER)

Hepatitis C

Russian Federation
Merck Sharp & Dohme LLC

Completed

A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)

Hepatitis C

3

Subscribe